[1]肖雅丽,李丛辉.超声造影联合miR-599水平在原发性肝癌TACE预后评估中的价值[J].中国医学物理学杂志,2024,41(4):439-443.[doi:DOI:10.3969/j.issn.1005-202X.2024.04.007]
　XIAO Yali,LI Conghui.Value of contrast-enhanced ultrasound combined with miR-599 level for prognostic evaluation of primary hepatic carcinoma treated with TACE[J].Chinese Journal of Medical Physics,2024,41(4):439-443.[doi:DOI:10.3969/j.issn.1005-202X.2024.04.007]
点击复制

超声造影联合miR-599水平在原发性肝癌TACE预后评估中的价值()
分享到：

《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]

卷:
41卷
期数:
2024年第4期
页码:
439-443
栏目:
医学影像物理
出版日期:
2024-04-25

文章信息/Info

Title:
Value of contrast-enhanced ultrasound combined with miR-599 level for prognostic evaluation of primary hepatic carcinoma treated with TACE
文章编号:
1005-202X（2024）04-0439-05
作者:
肖雅丽; 李丛辉
湘南学院附属医院超声科， 湖南 郴州 423000
Author(s):
XIAO Yali;  LI Conghui
Department of Ultrasound, Affiliated Hospital of Xiangnan University, Chenzhou 423000, China
关键词:
原发性肝癌; 经导管动脉栓塞术; 超声造影; 微小RNA-599; 治疗效果
Keywords:
Keywords: primary hepatic carcinoma transcatheter arterial chemoembolization contrast-enhanced ultrasound microRNA-599 therapeutic efficacy
分类号:
R735.7
DOI:
DOI:10.3969/j.issn.1005-202X.2024.04.007
文献标志码:
A
摘要:
【摘要】目的：探讨超声造影（CEUS）联合血清微小RNA-599（miR-599）评估原发性肝癌（PHC）经导管动脉栓塞（TACE）术后疗效的价值。方法：采用回顾性研究方法，选取接受TACE治疗的80例PHC患者进行研究分析。根据实体瘤疗效标准（RECIST）将患者分为有效组54例和无效组26例，分别于TACE后第7天、14天、1月、2月时采用CEUS检查患者的肿瘤病灶灭活率，于术前及术后第7天、14天、1月、2月时检查患者血清miR-599水平，以患者TACE术后2月时的数字减影血管造影检查结果作为金标准，计算CEUS评估疗效的价值，并采用单因素分析方法及多因素Logistic回归模型分析血清miR-599与PHC患者TACE治疗效果的关系。结果：80例接受TACE治疗的PHC患者，在接受治疗2月后进行评价，其中完全缓解9例、部分缓解45例、疾病稳定22例、疾病进展4例；有效组患者的年龄、体质量指数、TACE次数、Child-pugh分级、HBsAg结果与无效组比较，差异均无统计学意义（P>0.05）；有效组患者与无效组患者的术前甲胎蛋白水平、病灶数目、最大病灶直径、病理学分期、是否使用索菲拉尼的情况比较，差异均具有统计学意义（P<0.05）；术后1月时有效组的病灶灭活率为66.67%，术后2月时有效组患者的病灶灭活率为94.44%，有效组在术后1月、2月时的病灶灭活率显著高于无效组患者（P<0.05）；无效组患者在术前及术后第7天、14天、1月、2月的血清miR-599水平均显著低于有效组患者（P<0.05）；Logistic回归模型显示：术前miR-599低水平、术前AFP≥400 μg/L、病灶直径≥5.0 cm、病理学分期为ⅢA期是TACE治疗PHC患者疗效不佳的独立危险因素（P<0.05），使用索菲拉尼有利于提高TACE治疗PHC患者的效果（P<0.05）。结论：应用TACE治疗的PHC患者，采用CEUS动态观察病灶变化情况，能较为准确地评估其临床治疗效果，而血清miR-599水平越低的PHC患者TACE治疗效果越差，可将CEUS病灶观察结果与血清miR-599检测结合，对PHC患者TACE的治疗效果进行综合评价。
Abstract:
Abstract: Objective To explore the value of contrast-enhanced ultrasound (CEUS) combined with serum microRNA-599 (miR-599) in evaluating the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) in primary hepatic carcinoma (PHC). Methods A retrospective study was conducted on 80 PHC patients receiving TACE. According to response evaluation criteria in solid tumors (RECIST), the patients were divided into effective group (n=54) and ineffective group (n=26). CEUS was used to obtain the tumor lesion inactivation rate on the 7th day, 14th day, 1st month, and 2nd month after TACE and the serum miR-599 level was measured before TACE and on the 7th day, 14th day, 1st month, and 2nd month after TACE. The results of digital subtraction angiography at the 2nd month after TACE were taken as the gold standard to assess the value of CEUS in evaluation of therapeutic efficacy. The relationship between serum miR-599 and TACE outcome in PHC was analyzed using univariate analysis and multivariate Logistic regression model. Results The evaluation at 2 months after TACE showed that among 80 PHC patients treated with TACE, there were 9 cases of complete response, 45 of partial response, 22 of stable disease, and 4 of progressive disease. The differences in age, body mass index, TACE frequency, Child-pugh grade, and HBsAg result between effective group and ineffective group were trivial (P>0.05) while the two groups differed significantly in preoperative alpha-fetoprotein level, number of lesions, maximum lesion diameter, pathological staging, and whether to use Sofilanide (P<0.05). The lesion inactivation rates at the 1st and 2nd months after TACE were 66.67% and 94.44% in effective group, significantly higher than those in ineffective group (P<0.05). The serum miR-599 levels were significantly lower in ineffective group than in effective group preoperatively, and 7 days, 14 days, 1 month, 2 month postoperatively (P<0.05). The results of Logistic regression model showed that preoperative low miR-599 level, preoperative AFP ≥ 400 μg/L, lesion diameter ≥ 5.0 cm, and pathological staging of stage IIIA were independent risk factors for poor efficacy of TACE in PHC (P<0.05). Sofilanib could improve the efficacy of TACE in treating PHC (P<0.05). Conclusion For PHC patients undergoing TACE, the dynamic observation of lesion changes using CEUS can accurately evaluate the therapeutic effect in clinic. However, primary tumor patients with lower serum miR-599 level have poor response to TACE. Lesion observation using CEUS can be combined with serum miR-599 measurement to comprehensively evaluate the treatment outcome in PHC patients.

相似文献/References:

[1]侯勇,黄瑞彬,范医鲁.基于Flatten-Filter Free模式治疗原发性肝癌的剂量学研究[J].中国医学物理学杂志,2015,32(04):590.[doi:10.3969/j.issn.1005-202X.2015.04.030]
　[J].Chinese Journal of Medical Physics,2015,32(4):590.[doi:10.3969/j.issn.1005-202X.2015.04.030]
[2]侯勇,万振法,范医鲁.原发性肝癌不同弧度容积旋转调强与常规固定野调强剂量学比较[J].中国医学物理学杂志,2015,32(05):747.[doi:doi:10.3969/j.issn.1005-202X.2015.05.030]
　[J].Chinese Journal of Medical Physics,2015,32(4):747.[doi:doi:10.3969/j.issn.1005-202X.2015.05.030]
[3]刘亚,曾建挺,张艳林,等. 灌注式热化疗联合微球在原发性肝癌介入治疗中的价值[J].中国医学物理学杂志,2018,35(11):1339.[doi:DOI:10.3969/j.issn.1005-202X.2018.11.019]
　LIU Ya,ZENG Jianting,ZHANG Yanlin,et al. Value of perfusion thermo-chemotherapy combined with microspheres in the interventional treatment of primary liver cancer[J].Chinese Journal of Medical Physics,2018,35(4):1339.[doi:DOI:10.3969/j.issn.1005-202X.2018.11.019]

备注/Memo

备注/Memo:
【收稿日期】2023-11-23 【基金项目】湖南省教育厅科学研究项目（18C1026） 【作者简介】肖雅丽，主治医师，研究方向：超声介入，E-mail: xiaoyali202209@163.com 【通信作者】李丛辉，硕士，副主任医师，研究方向：超声诊断与介入治疗，E-mail: xx2020@foxmail.com
更新日期/Last Update: 2024-04-25